Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia

RL Gleason Jr, AW Caulk, D Seifu, JC Rosebush… - Journal of …, 2016 - Elsevier
Background HIV patients on highly-active antiretroviral therapy (HAART) have shown
elevated incidence of dyslipidemia, lipodystrophy, and markers of cardiovascular disease …
被引用次数：32 相关文章

Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia

RL Gleason, AW Caulk, D Seifu, JC Rosebush… - Journal of …, 2016 - infona.pl
HIV patients on highly-active antiretroviral therapy (HAART) have shown elevated incidence
of dyslipidemia, lipodystrophy, and markers of cardiovascular disease. Evidence is …
[PDF] academia.edu

[PDF][PDF] Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia

RL Gleason Jr, AW Caulk, D Seifu, JC Rosebush… - academia.edu
abstract Background: HIV patients on highly-active antiretroviral therapy (HAART) have
shown elevated incidence of dyslipidemia, lipodystrophy, and markers of cardiovascular …

Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia.

RLJ Gleason, AW Caulk, D Seifu, JC Rosebush… - 2016 - cabidigitallibrary.org
Background: HIV patients on highly-active antiretroviral therapy (HAART) have shown
elevated incidence of dyslipidemia, lipodystrophy, and markers of cardiovascular disease …

Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia

RL Gleason Jr, AW Caulk, D Seifu… - Journal of …, 2016 - pubmed.ncbi.nlm.nih.gov
Background HIV patients on highly-active antiretroviral therapy (HAART) have shown
elevated incidence of dyslipidemia, lipodystrophy, and markers of cardiovascular disease …

Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia.

RL Gleason Jr, AW Caulk, D Seifu… - Journal of …, 2016 - europepmc.org
Background HIV patients on highly-active antiretroviral therapy (HAART) have shown
elevated incidence of dyslipidemia, lipodystrophy, and markers of cardiovascular disease …

[引用][C] Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia

RL Gleason, AW Caulk, D Seifu… - Journal of …, 2016 - Elsevier Limited